Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three weekly shots go head to head in obesity trial

NCT ID NCT07834398

NEW Disease control Sponsor: Zagazig University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 22, 2026 · Last updated Sep 22, 2026

Summary

Researchers compare three weekly GLP-1 receptor agonist drugs, dulaglutide, semaglutide, and tirzepatide, in 150 obese adults without diabetes. Participants receive one of the drugs for six months. The trial measures changes in body weight, BMI, blood sugar, cholesterol, and liver function to see which drug works best.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
weekly GLP-1 receptor agonist drugs: dulaglutide, semaglutide, and tirzepatide
What this could lead to
If one drug helps more, doctors could choose the most effective weekly option for weight loss in people with obesity who do not have diabetes.
What could go wrong
This is a six-month study of 150 people, so it cannot show long-term weight maintenance or rare side effects. GLP-1 drugs commonly cause nausea and digestive issues, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

150 people

The number who actually took part.

Started

Nov 2025

Finished

Apr 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects (above 18 years old) obese body mass index (BMI) above 30 Exclusion Criteria: * Subjects with liver disease, renal dysfunction diabetes, pancreatic diseases ,thyroid disorder or goiter psychological diseases like depression and pregnant women, and Patients who will refuse

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-diabetec obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-diabetec obesity Obesity (disorder)

Contacts and locations

Locations

  • New Najran General Hospital

    Najran, 55461, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.